{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:14Z","timestamp":1789685534890,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40744-024-00657-2","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T14:01:44Z","timestamp":1710770504000},"page":"633-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE\u00a02 Randomized Clinical Trial"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Asnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5727-7199","authenticated-orcid":false,"given":"Jacob","family":"Aelion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Stakias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Drogaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","volume":"76","author":"LE Kristensen","year":"2017","unstructured":"Kristensen LE, Jorgensen TS, Christensen R, et al. Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76:1495\u2013501.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"657_CR3","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-7.","journal-title":"Ann Rheum Dis"},{"key":"657_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62:970\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407\u201313.","journal-title":"Ann Rheum Dis"},{"key":"657_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs"},{"key":"657_CR8","unstructured":"SKYRIZI (risankizumab-rzaa) Prescribing information. Abbvie Inc.; 2023. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed September 1, 2023."},{"key":"657_CR9","unstructured":"SKYRIZI (risankizumab). Summary of Product Characteristics. Prescribing information. Abbvie Inc.; 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf. Accessed September 1, 2023."},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a01 trial. Ann Rheum Dis. 2022;81:225\u201331.","journal-title":"Ann Rheum Dis"},{"key":"657_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a02 trial. Ann Rheum Dis. 2022;81:351\u20138.","journal-title":"Ann Rheum Dis"},{"key":"657_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a01 study. Rheumatology (Oxford). 2023;62:2113\u201321.","journal-title":"Rheumatology (Oxford)"},{"key":"657_CR13","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6st\u00f6r","year":"2023","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a02 study. Rheumatology (Oxford). 2023;62:2122\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"657_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, FitzGerald O, Merola JF, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70:345\u201355.","journal-title":"Arthritis Rheumatol"},{"key":"657_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65:1213\u201323.","journal-title":"Arthritis Rheum"},{"key":"657_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Stolshek BS, Rebello S, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017;36:895\u2013901.","journal-title":"Clin Rheumatol"},{"key":"657_CR17","first-page":"157","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157\u201360.","journal-title":"Acta Biomed"},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1038\/s41598-023-31709-2","volume":"13","author":"K Agyapon-Ntra","year":"2023","unstructured":"Agyapon-Ntra K, McSharry PE. A global analysis of the effectiveness of policy responses to COVID-19. Sci Rep. 2023;13:5629.","journal-title":"Sci Rep"},{"key":"657_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjd.12744","volume":"170","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Schenfeld J, Accortt NA, et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005\u201309. Br J Dermatol. 2014;170:366\u201373.","journal-title":"Br J Dermatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00657-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:30:49Z","timestamp":1716391849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00657-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00657-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew \u00d6st\u00f6r has received speaker or consulting fees and\/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. Filip Van den Bosch has received speaker and\/or consulting fees from AbbVie, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. Kim Papp has received research funds from AbbVie, Aceleryn, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. He is a consultant for AbbVie, Aceleryn, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Forward Pharma, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. He is a speaker for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB. He is a committee member for PSOLAR (Psoriasis Longitudinal Assessment and Registry) and PURE (registry of patients with moderate-to-severe chronic plaque psoriasis in Latin America and Canada). Cecilia Asnal has received honoraria or fees for serving on advisory boards or as a speaker, as well as research support from AbbVie, Amgen, Genentech, Janssen, Lilly, Pfizer, Roche, and R-Pharm. Ricardo Blanco has received grants or research support from AbbVie, Merck, and Roche. He has received consultation fees or honoraria for serving as a speaker for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer and Roche. Jacob Aelion has received grants or research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galapagos\/Gilead, Genentech, GlaxoSmithKline, Lilly, Mallinckrodt, Nektar Therapeutics, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche, Sanofi, Selecta Biosciences, and UCB. Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, and Byron Padilla are full-time employees of AbbVie and may hold AbbVie stock or stock options or AbbVie patents. Alan Kivitz has received consulting fees from Horizon, Frescenius Kabi, Pfizer, GlaxoSmithKline, Janssen, Selecta, Genzyme, Gilead, Synact, Takeda, and Grunenthal; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GlaxoSmithKline, Eli Lilly, Pfizer, AbbVie, Amgen, and UCB; has served on boards or advisory boards for Horizon, Janssen, Chemocentryx, Princeton Biopartners, UCB, and Novartis; and has stock or stock options in Pfizer, GSK, Gilead, Novartis, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The independent ethics committee or institutional review board (see Supplemental Table\u00a0) at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent at screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}